

## [β2 Microglobulin](#)

<b>Accreditation Status:</b>	<a href="#">UKAS Schedule of Accreditation</a>												
<b>Date Scheme started:</b>	1987												
<b>Clinical Applicability:</b>	Diagnosis and monitoring of B-cell malignancies												
<b>Analytes:</b>	β2 Microglobulin												
<b>Units for Reporting:</b>	mg/L												
<b>Samples Distributed:</b>	Liquid format. Normal and pathological human serum												
<b>Number of Distributions per year:</b>	6												
<b>Number of Samples per Distribution:</b>	2												
<b>Frequency of Distributions:</b>	Every two months as outlined in the <a href="#">Distribution Schedule</a>												
<b>Schedule of Analysis:</b>	<a href="#">Data entry</a> is via the web for the submission of results. Data analysis is commenced 21 days after sample dispatch. Late returns are accepted and will contribute to the laboratory's cumulative performance statistics												
<b>Data Analysis:</b>	All Laboratory Trimmed Mean (ALTM) with truncation at 2SD, SD, and CV%. Reports also show method specific statistics. Individual laboratory performance is expressed in terms of MRBIS, SDBIS, and MRVIS.  Chosen Coefficient of Variation for β2 Microglobulin is 7%												
<b>Performance Scoring:</b>	MRVIS												
<b>Criteria of Performance:</b>	Laboratory performance is classified in terms of the MRVIS over a running analytical window of 6 Distributions (12 months) <table> <tr> <td>Ideal</td> <td>MRVIS</td> <td>&lt;50</td> </tr> <tr> <td>Good</td> <td></td> <td>50 - 100</td> </tr> <tr> <td>Adequate</td> <td></td> <td>101 - 200</td> </tr> <tr> <td>Poor</td> <td></td> <td>&gt;200 or SDBIS &gt;200</td> </tr> </table>	Ideal	MRVIS	<50	Good		50 - 100	Adequate		101 - 200	Poor		>200 or SDBIS >200
Ideal	MRVIS	<50											
Good		50 - 100											
Adequate		101 - 200											
Poor		>200 or SDBIS >200											
<b>Persistent Poor Performance:</b>	Defined as being in the Poor Performance category for two or more successive Distributions												